Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Method of treatment of aggression
US9801887B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9801887-B2 |
| Application number | US-201313951642-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2013 |
| Priority date | Dec 19, 2008 |
| Publication date | Oct 31, 2017 |
| Grant date | Oct 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating impulsive aggression in an attention deficit hyperactivity disorder (ADHD) patient, comprising: (a) selecting a patient with ADHD as the sole condition and manifesting impulsive aggression not controlled by ADHD treatment; and (b) administering 10 mg/day to 200 mg/day of molindone to the ADHD patient, wherein the administration decreases instances of impulsivity. 2. The method of claim 1 , wherein the molindone is administered at a dose that is 50% or less of a dose indicated for the use of molindone as an antipsychotic agent. 3. The method of claim 1 , wherein the molindone is administered in a dose range of from 15 mg/day to 120 mg/day. 4. The method of claim 2 , wherein the administration decreases the side effects associated with molindone. 5. The method of claim 4 , wherein the side effects are selected from drowsiness, depression, hyperactivity, euphoria, extrapyramidal reactions, akathisia, akinesia, dystonic syndrome, tardive dyskinesia, tachycardia, nausea, dry mouth, urinary retention, and constipation. 6. The method of claim 2 , wherein the administration results in reduction of undesirable behavior and intolerable side effects. 7. The method of claim 1 , wherein the patient is a child.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia · CPC title
Drugs for disorders of the nervous system · CPC title
Hypnotics; Sedatives · CPC title
- A61K31/5377Primary
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9801887B2 cover?
- The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.
- Who is the assignee on this patent?
- Supernus Pharmaceuticals Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Oct 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).